TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03270696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of propofol and rocuronium
Description: compare the tidal volume applied from starting facemask ventilation under 15cmH2O of PCV for 1 minute according to administrating propofol and rocuronium simultaneously, or ordinally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: administration of propofol and rocuronium
Description: compare the tidal volume applied from starting facemask ventilation under 15cmH2O of PCV for 1 minute according to administrating propofol and rocuronium simultaneously, or ordinally
Study: NCT03124134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis200
Description: Encapsulated hydrogel

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis200
Description: Encapsulated hydrogel

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelesis200
Description: Encapsulated hydrogel

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water, only (placebo)
Description: 300 mL of water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water, only (placebo)
Description: 300 mL of water

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water, only (placebo)
Description: 300 mL of water
Study: NCT03929809

Intervention type: DEVICE
Intervention: Cochlear Implant
Description: adults with unilateral hearing loss who wish to regain bilateral hearing will be implanted with a cochlear implant on their deafened ear.
Study: NCT00440115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High intensity disease management
Description: Health education mailings, 6 motivation interviews/counseling

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low intensity disease management
Description: Health education mailings, one motivation interview/counseling

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Comparison group
Description: Health education mailings

Intervention type: DRUG
Group type: OTHER
Intervention: Bupropion
Description: Buproprion or Nicotine Replacement Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Buproprion or Nicotine Replacement Therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Buproprion or Nicotine Replacement Therapy
Study: NCT00622687

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iloprost
Description: 0.5-2 ng/kg x min for 6hours a day for 21 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iloprost low dose
Description: 0.5 ng/kg x min over 6 h per day for 21 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iloprost therapy up to 2 ng/kg x min
Description: starting therapy at doses of 0.5 ng/kg x min, increase the dose every two days for 0.5 ng/kg x min up to the maximally tolerated dose or to 2 ng/kg x min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iloprost therapy up to 2 ng/kg x min
Description: starting therapy at doses of 0.5 ng/kg x min, increase the dose every two days for 0.5 ng/kg x min up to the maximally tolerated dose or to 2 ng/kg x min
Study: NCT02802215

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Metformin group will receive 1500 mg of metformin per day orally ( 500 mg every 8hrs in the middle of meal) starting from 12th week of gestation till delivery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (folic acid )
Description: 500 micro gram of folic acid every 8 hrs
Study: NCT00183196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: Naltrexone (50 mg/day) plus gabapentin placebo in divided doses for the first 6weeks. Naltrexone (50 mg/day) for rest of 16-weeks
Study: NCT03287492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Informational Intervention
Description: Receive QPS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Informational Intervention
Description: Receive GIS

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03113487

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Modified Vaccinia Virus Ankara Vaccine Expressing p53
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT03235349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir
Description: Coformulated tablet for oral administration
Study: NCT01115049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorobutanol, hexetidine
Description: 3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: 3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash
Study: NCT03502278

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Islamic Trauma Healing
Description: A lay-led, six-session group intervention that combines empirically supported exposure-based and cognitive restructuring techniques with Islamic principles
Study: NCT02341989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin Etoposide and Cisplatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Study: NCT02345252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/RPV/TAF
Description: 200/25/25 mg FDC tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/RPV/TAF
Description: 200/25/25 mg FDC tablets administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/RPV/TDF Placebo
Description: Tablets administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/RPV/TDF
Description: 200/25/300 mg FDC tablets administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/RPV/TAF Placebo
Description: Tablets administered orally once daily
Study: NCT02515864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FYU-981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin Placebo
Study: NCT04156750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3556050
Description: Administered orally.
Study: NCT00183196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone plus Gabapentin
Description: naltrexone (50 mg/day) for 16-weeks plus gabapentin (up to 1200 mg/day in divided doses) for the first 6 weeks

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inactive Placebo
Description: Placebo
Study: NCT03239496

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV
Description: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: f-IPV
Description: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: f-IPV
Description: Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
Study: NCT01235715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evicel fibrin sealant
Description: Used for hemostasis to control bleeding. It has been shown to stop bleeding in 2 minutes or less. It is a combination of a biologic activated component containing human fibrinogen and topical thrombin functioning on wet, actively bleeding tissue.
Study: NCT02074267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbatin
Description: Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300\~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurontin
Description: Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300\~800 mg three times/day over 4 to 25 days.~The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period.
Study: NCT00403949

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azelaic acid 15% gel
Description: gel, applied once daily, for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Non-active base from azelaic acid 15% gel
Description: gel, apply once daily for six weeks
Study: NCT04533906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coldamaris lozenges
Description: sucking carageenan containing lozenge
Study: NCT01074645

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Tenofovir disoproxil fumarate (TDF)
Description: Tenofovir 300mg/day for 3 month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF)
Description: Tenofovir 300mg/day for 3 month
Study: NCT02733627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1467335

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02576717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RPC1063
Study: NCT03255863

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: Patient Self reported questionnaire filled in.
Study: NCT01177163

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 28431754 300 mg/placebo
Description: one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ 28431754 100 mg/placebo
Description: one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
Study: NCT02079337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rocuronium

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rocuronium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugammadex

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00406016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI355
Study: NCT00768352

Intervention type: OTHER
Group type: OTHER
Intervention: Educational intervention
Description: An educational intervention which will consist of a standardized PowerPoint presentation that will cover general mental health topics such as depression and substance abuse. The presentation will also include discussion of common and validated mental health screening and assessment tools, as well as how to use these tools in a clinical setting. An educational packet will be provided to the residents and will include the screening tools, information on motivational interviewing and the behavioral stages of change, information on common medications prescribed for mental health disorders, and a bibliography of reputable resources for mental health topics.
Study: NCT03658863

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic ultrasound
Description: Evaluation of bile ducts with endoscope with special ultrasonographic function

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: intraoperative cholangiography
Description: evaluation of bile ducts by injecting radiocontrast media to cystic duct during laparoscopic cholecystectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: evaluation of bile ducts by injecting radiocontrast media to common bile duct via endoscope inserted to duodenum

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: evaluation of bile ducts by injecting radiocontrast media to common bile duct via endoscope inserted to duodenum

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound endoscope
Description: Endoscope with built-in ultrasound function
Study: NCT02553655

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 4x 5min Limb Preconditioning
Description: A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 millimeters of mercury (mmHg) above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 5min and is followed by 5 minutes of reperfusion/rest. This will be repeated 4 times.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3x 10min Limb Preconditioning
Description: A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 mmHg above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of reperfusion/rest. This will be repeated 3 times.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: 3x 10min Sham Preconditioning
Description: A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 40 mmHg, sufficient to apply pressure but not affect blood flow. The presence of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of rest. This will be repeated 3 times.
Study: NCT01858987

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stapler hepatectomy
Description: Liver resection using vascular stapler for transection of the parenchyma

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LigaSure hepatectomy
Description: Liver resection using LigaSure for transection of the parenchyma

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ligasure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vascular staple
Study: NCT03877926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909
Description: AV7909 consists of Anthrax Vaccine Adsorbed (AVA) drug substance and CPG 7909 adjuvant. AVA drug substance in AV7909 is similar in composition and manufactured using the same process as commercial BioThrax® vaccine. BioThrax is licensed for post-exposure prophylaxis of anthrax disease. CPG 7909 is an immunostimulatory synthetic oligodeoxynucleotide that functions as an adjuvant. It is designed to induce an enhanced immune response.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909
Description: AV7909 consists of Anthrax Vaccine Adsorbed (AVA) drug substance and CPG 7909 adjuvant. AVA drug substance in AV7909 is similar in composition and manufactured using the same process as commercial BioThrax® vaccine. BioThrax is licensed for post-exposure prophylaxis of anthrax disease. CPG 7909 is an immunostimulatory synthetic oligodeoxynucleotide that functions as an adjuvant. It is designed to induce an enhanced immune response.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV7909
Description: AV7909 consists of Anthrax Vaccine Adsorbed (AVA) drug substance and CPG 7909 adjuvant. AVA drug substance in AV7909 is similar in composition and manufactured using the same process as commercial BioThrax® vaccine. BioThrax is licensed for post-exposure prophylaxis of anthrax disease. CPG 7909 is an immunostimulatory synthetic oligodeoxynucleotide that functions as an adjuvant. It is designed to induce an enhanced immune response.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BioThrax
Description: BioThrax vaccine (Anthrax Vaccine Adsorbed; AVA) is licensed for post-exposure prophylaxis of anthrax disease.
Study: NCT02588079

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy
Study: NCT02268539

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ablation
Description: Ablation ranging from 20-25 watts / 30-45 seconds

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ablation
Description: Ablation ranging from 20-25 watts / 30-45 seconds

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ablation
Description: Ablation ranging from 20-25 watts / 30-45 seconds

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ablation
Description: Ablation ranging from 20-25 watts / 30-45 seconds
Study: NCT03245307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib at a dosage of 750mg will be administered daily from day 9 of phase A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine GTIS
Description: Nifedipine at a dosage of 30mg will be administered at day 1 and day 14 of phase A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin Potassium
Description: Nifedipine at a dosage of 3mg will be administered at day 3 and day 16 of phase A
Study: NCT03554317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate
Description: Depot (DEPO)-Testosterone Injection, for intramuscular (IM) injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depot (DEPO)-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab Injection, 100 mg/10 mL (10 mg/mL) or 40 mg/4 mL (10 mg/mL), is a clear to opalescent, colorless to pale yellow liquid, which may contain light (few) particulates. The drug product is a sterile, non-pyrogenic, single-use, isotonic aqueous solution formulated at 10 mg/mL in sodium citrate, sodium chloride, mannitol, diethylenetriaminepentacetic acid (pentetic acid), and polysorbate 80 (Tween 80), at potential hydrogen (pH) 6.0 and includes an overfill to account for vial, needle, and syringe holdup. It is supplied in 10-cc Type I flint glass vials, stoppered with butyl rubber. The clinical study product is a sterile solution to be administered through parenteral intravenous infusion.
Study: NCT03297619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness and Acceptance Workbook for Social Anxiety and Shyness
Description: Participants assigned to this condition will be asked to read this self-help book over an 8-week period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Shyness and Social Anxiety Workbook
Description: Participants assigned to this condition will be asked to read this self-help book over an 8-week period (with some chapters omitted).
Study: NCT04529395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blending of essential oils
Description: The mixture of essential oils will be applied to the arch of the foot by massage every 8 hours (3 times a day, 6 drops per application with 3 drops per foot).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apricot vegetable oil
Description: The apricot vegetable oil will be applied to the arch of the foot by massage every 8 hours (3 times a day, 6 drops per application with 3 drops per foot).
Study: NCT00006371

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aminoglutethimide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketoconazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic hydrocortisone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic hydrocortisone
Study: NCT02506231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01987726

Intervention type: OTHER
Intervention: cytology specimen collection procedure
Description: Undergo collection of CTCs for NGS and FMI testing, respectively.The most recent tumor sample collected from the patient with enough tissue to perform NGS testing will be selected. Tumor from a metastatic or recurrent cancer lesion is preferred but not required. Tumor collection is for standard of care purposes and thus not detailed in this protocol.For each tissue specimen, a representative H\&E stained section will be evaluated by a qualified pathologist to confirm the histopathological diagnosis of cancer and to make a quantitative estimate of the proportion of the specimen that is tumor-related cells and the proportion that is non-tumor cells.

Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: 2 tubes of 7.5 mL blood samples each will be collected at time tumor tissue is sent to FMI and sent to Cynvenio Biosystems, Inc for CTC isolation and analysis. Patient CTCs will be recovered using Cynvenio CTC flow cell technology (Cynvenio Biosystems, Inc.) and enumerated using a combination of CD45, DAPI and cytokeratin staining.1 DNA will be isolated from CTCs and amplified using Φ-29 whole genome amplification (GE Healthcare). Sequencing to be performed by FoundationOne™ protocol.
Study: NCT04712084

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positive pressure
Description: Inspiratory support of 8 cmH2O was applied associated with PEEP at 6 cmH2O. After extubation, same support was applied by facemask for 3 minutes
Study: NCT02192294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Bosutinib
Description: a single dose of 500 mg oral bosutinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of bosutinib
Description: a single dose of 120 mg of bosutinib intravenous infusion (1 hour)